Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12872504 | 0.76 | HTR1A (0.53) | MAPTHTR1A | |
| SCHEMBL14319076 | 0.76 | SMN1; SMN2 (0.39) | MAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL23342005 | 0.76 | MAPT (0.34) | MAPTHTR1AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL20346243 | 0.75 | HRH3 (0.44) | MAPT | |
| SCHEMBL25895293 | 0.75 | CHRNB2 (0.38) | MAPTHTR1AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL18705032 | 0.72 | HRH3 (0.36) | MAPTHTR1AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL22152624 | 0.72 | KDM4E (0.44) | HTR1A | |
| SCHEMBL21016903 | 0.71 | CYP1A2 (0.52) | MAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL8530598 | 0.71 | CA2 (0.43) | — | |
| SCHEMBL17734173 | 0.71 | MAPT (0.58) | MAPTKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | MAPT 1938/4885HTR1A 2548/4885KMT2A 1388/4885 |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | RET, BRAF, ROR1 | MAPT 1941/4885HTR1A 2508/4885KMT2A 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.